1-8 of 8
Tomoko Smyth
Close
Sort by
Journal Articles

Epigenetic Priming By Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-Cell Lymphoma

George Ward, Zhiqiang Zhang, Simone Jueliger, Ilya Potapov, Matthew P Davis, Adam Boxall, Jason A Taylor, Harold N. Keer, Andrea Biondo, John F Lyons, Martin Sims, Tomoko Smyth
Journal: Blood
Blood (2023) 142 (Supplement 1): 1439.
https://doi.org/10.1182/blood-2023-186712
Published: 2023
Journal Articles

ASTX660-01 Phase 2: A Case Study of Tolinapant-Induced Pseudoprogression in CTCL

Brian Poligone, Simone Jueliger, Matthew P Davis, Ilya Potapov, George Ward, Tomoko Smyth, Jason A Taylor, Harold N. Keer, Martin Sims
Journal: Blood
Blood (2023) 142 (Supplement 1): 6205.
https://doi.org/10.1182/blood-2023-179195
Published: 2023
Journal Articles

Tolinapant, a Non-Peptidomimetic Antagonist of Inhibitors of Apoptosis Proteins, cIAP1/2 and XIAP, in Combination with the Hypomethylating Agents, Azacytidine and Decitabine Are Highly Synergistic in in Vitro Models of T Cell Lymphoma

John Sanil Manavalan, Ipsita Pal, Aidan Pursley, George A. Ward, Tomoko Smyth, Martin Sims, Jason A. Taylor, David J Feith, Thomas P. Loughran, Jr., Owen A. O'Connor, Enrica Marchi
Journal: Blood
Blood (2022) 140 (Supplement 1): 11552–11553.
https://doi.org/10.1182/blood-2022-169906
Published: 2022
Journal Articles

Combining the IAP Antagonist Tolinapant with a DNA Hypomethylating Agent Enhances Immunogenic Cell Death in Preclinical Models of T-Cell Lymphoma

George A. Ward, Simone Jueliger, Martin Sims, Matthew Davis, Adam Boxall, Harpreet Saini, Jason A. Taylor, Andrea Biondo, John F. Lyons, Tomoko Smyth
Journal: Blood
Blood (2021) 138 (Supplement 1): 3986.
https://doi.org/10.1182/blood-2021-152176
Published: 2021
Journal Articles

Tolinapant (ASTX660), a Non-Peptidomimetic Antagonist of cIAP1/2 and XIAP, and the HDAC Inhibitor Romidepsin Are Synergistic in in Vitro Models of T Cell Lymphoma

John S Manavalan, Ipsita Pal, Aidan Pursley, George A. Ward, Tomoko Smyth, Martin Sims, David J Feith, Thomas P. Loughran, Jr., Owen A. O'Connor, Enrica Marchi
Journal: Blood
Blood (2021) 138 (Supplement 1): 4356.
https://doi.org/10.1182/blood-2021-153451
Published: 2021
Journal Articles

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells

Ruriko Tanaka, Matthew S. Squires, Shinya Kimura, Asumi Yokota, Rina Nagao, Takahiro Yamauchi, Miki Takeuchi, Hisayuki Yao, Matthias Reule, Tomoko Smyth, John F. Lyons, Neil T. Thompson, Eishi Ashihara, Oliver G. Ottmann, Taira Maekawa
Journal: Blood
Blood (2010) 116 (12): 2089–2095.
https://doi.org/10.1182/blood-2009-03-211466
Published: 2010
Includes: Supplemental data
Journal Articles

Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.

Ruriko Tanaka, MMSc, Matthew S Squires, PhD, Shinya Kimura, MD, PhD, Asumi Yokota, MMSc, Kirsty Mallett, PhD, Tomoko Smyth, PhD, Neil T Thompson, PhD, Rina Nagao, Takahiro Yamauchi, MD, Takashi Ushiki, MD, John F Lyons, PhD, Taira Maekawa, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1104.
https://doi.org/10.1182/blood.V112.11.1104.1104
Published: 2008
Journal Articles

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Matthew S. Squires, PhD, Jayne E. Curry, Mark A. Dawson, Mike A. Scott, Kelly Barber, Matthias Reule, Tomoko Smyth, Nicola Wallis, Murray Yule, Neil T. Thompson, John F. Lyons, Anthony R. Green
Journal: Blood
Blood (2007) 110 (11): 3537.
https://doi.org/10.1182/blood.V110.11.3537.3537
Published: 2007